Neurolytic Celiac Plexus Block for Treatment of Cancer Pain

Eisenberg, Elon; Carr, Daniel B.; Chalmers, T. C.

doi:10.1213/00000539-199502000-00015

Cited by 101 publications

(187 citation statements)

References 19 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…NCPB is likely to have prompt and long-lasting analgesic efficacy for pancreatic cancer. A meta-analysis, composed mainly of retrospective studies, suggests that NCPB has durable (at least 3 months) partial or complete pain relief in approximately 90% of patients with pancreatic and other intra-abdominal cancers [5]. While the administration of NCPB is typically reserved for patients with ongoing significant pain despite optimized opioid therapy (maximum analgesia achievable without intolerable opioid-related adverse effects), a randomized, double-blind, controlled trial evaluated the implementation of NCPB while opioid therapy was being initiated or increased [6].…”

Section: Pain Controlmentioning

confidence: 99%

Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?

2008

View full text Add to dashboard Cite

Pancreatic cancer is the fourth most common cause of adult cancer death in the U.S. The high mortality rate from pancreatic cancer is a result of the high incidence of metastatic disease at the time of diagnosis, an often fulminant clinical course, and the lack of adequate systemic therapies. Unfortunately, only 5%-25% of patients present with tumors amenable to resection. The median diseasefree survival interval following resection for operable pancreatic cancer is 13.4 months for patients treated with adjuvant gemcitabine and 6.9 months for untreated patients. A much higher percentage of patients present with metastatic disease (40%-45%) or locally advanced disease (40%), and have median survival times of 3-6 months or 8 -12 months, respectively. The frustrating lack of significant clinical advancements in the treatment of metastatic pancreatic cancer remains one of medical oncology's biggest disappointments. The past decade-long frustration has resulted in regulators, investigators, and practicing oncologists gradually lowering their standards/expectations with regard to interpreting clinical trials. Two of the more important examples of this include the approval of gemcitabine plus erlotinib and the use of a progressionfree survival advantage to defend the use of gemcitabine plus oxaliplatin. Given the marginal benefit of systemic antineoplastics, a scholarly review inclusive of other palliative strategies will help oncologists optimize the care of pancreatic cancer patients. This article examines the existing evidence in support of a role for palliative therapy in metastatic pancreatic cancer, describes recent developments with newer chemotherapeutic and molecular-targeted agents, and explores future study designs. The Oncologist 2008;13:562-576

show abstract

Section: Pain Controlmentioning

confidence: 99%

Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?

2008

View full text Add to dashboard Cite

show abstract

“…В метаанализе, проведенном E. Eisenberg, оце нена эффективность и безопасность НЛ по резуль татам публикаций в 59 статьях, отображающих ин формацию о 1117 пациентах, перенесших чрескож ный НЛ [16]. Отличные результаты были достигну ты в 89% случаев с полным эффектом, реализован ным в течение первых 2 нед; у 90% пациентов, пере живших 3 мес с момента выполнения НЛ, эффект был частичным, равно как и у 70% больных из числа умерших в ближайшие 3 мес.…”

Section: Abstract: Pain Syndrome Pain Management Endoscopic Ultrasounclassified

The factors influencing dynamics of pain syndrome and the method for the assessment of the effectiveness of the coeliac plexus block with subsequent neurolysis in the patients presenting with chronic upper abdominal pain syndrome

Burdyukov¹,

Давыдов²,

Yurichev³

et al. 2016

Dok. gastroenterol.

View full text Add to dashboard Cite

“…73 Interventional therapies are also available to treat cancer-related pain, and are particularly efective in severe cases that are refractory to systemic analgesics and cases in which intolerable side efects limit medication use. Celiac plexus blocks can provide long-lasting beneft for 70%-90% of patients with pancreatic and other abdominal malignancies, 74 and hypogastric plexus blocks can be efective in chronic cancer-related pelvic pain. 75 Intrathecal pumps deliver opioids directly into the subarachnoid space, achieving equianalgesic efect at much lower doses than do systemic administrations, thereby decreasing the risk of opioid dose-related adverse efects.…”

Section: Reviewmentioning

confidence: 99%

Cancer-related pain management in clinical oncology

Cipta¹,

Pietras²,

Weiss³

et al. 2015

J Community Support Oncol

View full text Add to dashboard Cite

Uncontrolled pain is one of the most feared and debilitating symptoms among cancer patients, and many suffer unnecessarily from suboptimal pain control. Cancer-related pain is often multidimensional and can affect all aspects of a patient's life. Hence, achieving adequate pain relief among cancer patients involves a proper assessment of psychosocial, spiritual, and physical pain issues, matched with an individualized treatment plan involving pharmacologic, nonpharmacologic, and procedural therapies when appropriate. Providing effective pain relief can help ease the overall burden of disease among oncology patients while helping them tolerate cancer-directed therapies and achieve the most optimal quality of life throughout all phases of the disease continuum. In this review, the authors will discuss the syndromes, assessment of, and treatment for cancer-related pain in the outpatient setting.

show abstract

Neurolytic Celiac Plexus Block for Treatment of Cancer Pain

Cited by 101 publications

References 19 publications

Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?

Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?

The factors influencing dynamics of pain syndrome and the method for the assessment of the effectiveness of the coeliac plexus block with subsequent neurolysis in the patients presenting with chronic upper abdominal pain syndrome

Cancer-related pain management in clinical oncology

Contact Info

Product

Resources

About